ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+39.51%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$340M
AUM Growth
+$340M
(-1.7%)
Cap. Flow
-$44M
Cap. Flow
% of AUM
-12.92%
Top 10 Holdings %
Top 10 Hldgs %
53.95%
Holding
62
New
15
Increased
11
Reduced
11
Closed
19
Top Buys
| 1 |
SAGE
Sage Therapeutics
SAGE
|
$13.8M |
| 2 |
CMPS
Compass Pathways
CMPS
|
$13.6M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$12.1M |
| 4 |
89bio
ETNB
|
$10.7M |
| 5 |
Celldex Therapeutics
CLDX
|
$8.08M |
Top Sells
| 1 |
Adverum Biotechnologies
ADVM
|
$36.5M |
| 2 |
BioXcel Therapeutics
BTAI
|
$18.1M |
| 3 |
ADAP
Adaptimmune Therapeutics
ADAP
|
$11.7M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$9.05M |
| 5 |
Ascendis Pharma
ASND
|
$8.21M |
Sector Composition
| 1 | Healthcare | 79.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Merus
MRUS
$4.98B
| – | – | -460,000 | Closed | -$7.4M |
|
52
uniQure
QURE
$896M
| – | – | -60,000 | Closed | -$2.7M |
|
53
Vir Biotechnology
VIR
$686M
| – | – | -127,000 | Closed | -$5.2M |
|
54
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – | 0 | – | – |
|
|
FUSN
55
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| – | – | -135,000 | Closed | -$2.36M |
|
|
EIGR
56
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – | -292,500 | Closed | -$2.81M |
|
|
RETA
57
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – | -15,300 | Closed | -$2.39M |
|
|
BLU
58
DELISTED
BELLUS Health Inc.
BLU
| – | – | -765,000 | Closed | -$7.87M |
|
|
STSA
59
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| – | – | -35,000 | Closed | -$1.01M |
|
|
AKUS
60
DELISTED
Akouos, Inc. Common Stock
AKUS
| – | – | -22,200 | Closed | -$500K |
|
|
DRNA
61
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| – | – | -170,000 | Closed | -$4.32M |
|
|
KDMN
62
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – | -1,280,000 | Closed | -$6.55M |
|